Viking Therapeutics, Inc. (VKTX) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 San Diego, CA, 미국. 현재 CEO는 Brian Lian.
VKTX 을(를) 보유 IPO 날짜 2015-04-28, 45 명의 정규직 직원, 에 상장 NASDAQ Capital Marke, 시가총액 $4.1B.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, dedicated to developing novel therapies for metabolic and endocrine disorders. The company's lead candidate, VK2809, is an orally available thyroid hormone receptor beta agonist currently in Phase IIb trials for non-alcoholic steatohepatitis and fatty liver disease. Viking's pipeline also includes VK5211, a selective androgen receptor modulator in Phase II development for hip fracture recovery; VK0612, a Phase IIb-ready candidate for type 2 diabetes; and VK0214, another thyroid hormone receptor beta agonist for X-linked adrenoleukodystrophy. Founded in 2012, the company focuses on addressing significant unmet medical needs in metabolic and endocrine disease treatment.
